Outset Medical EVP sells shares to cover taxes

Outset Medical, Inc. executive Marc Nash reported two sales of company common stock.

Rhea-AI Filing Summary

Outset Medical, Inc. executive Marc Nash reported two sales of company common stock. On January 20, 2026, he sold 5,375 shares at $5.12 per share, followed by a sale of 980 shares at $4.98 per share on January 21, 2026, all held directly.

The footnote explains these 6,355 shares were sold to cover partial tax withholding obligations tied to the vesting of 14,839 RSU-based shares granted on June 10, 2025, and that the transactions did not represent discretionary trades by Nash. After these sales, he directly owned 41,805 shares of Outset Medical common stock.

Insider Trade Summary

Net Seller: 6,355 shares

Net Sell 2 txns

Insider Nash Marc

Role EVP Operations R&D & Service

Sold 6,355 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock	980	$4.98	$5K
Sale	Common Stock	5,375	$5.12	$28K

Holdings After Transaction: Common Stock — 41,805 shares (Direct)

Footnotes (1)

1. F1. Required number of shares sold by the reporting person to cover partial tax withholding obligations in connection with the vesting of an aggregate of 14,839 shares of Common Stock underlying RSUs granted to the reporting person on June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Outset Medical (OM) report for Marc Nash?

Outset Medical reported that Marc Nash, EVP Operations R&D & Service, sold a total of 6,355 shares of the companys common stock in two transactions on January 20 and 21, 2026, and continued to hold shares directly afterward.

How many Outset Medical (OM) shares did Marc Nash sell and at what prices?

Marc Nash sold 5,375 shares of common stock at $5.12 per share on January 20, 2026, and 980 shares at $4.98 per share on January 21, 2026, for a total of 6,355 shares.

Why were Marc Nashs Outset Medical (OM) shares sold according to the Form 4?

The filing states the shares were sold to cover partial tax withholding obligations related to the vesting of 14,839 RSU-based shares, through a sell to cover transaction. It further notes that these sales do not represent discretionary trades by Marc Nash.

How many Outset Medical (OM) shares does Marc Nash hold after these transactions?

After the reported transactions, Marc Nash directly beneficially owned 41,805 shares of Outset Medical common stock.

What is Marc Nashs role at Outset Medical (OM)?

Marc Nash is reported as an officer of Outset Medical with the title EVP Operations R&D & Service, and is not listed as a director or 10% owner.

Were Marc Nash's Outset Medical share sales under a 10b5-1 trading plan?

The content shows the standard checkbox describing Rule 10b5-1(c) plans, but does not indicate that these particular sales were made under such a plan. Instead, the footnote specifies they were sell-to-cover transactions for tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 07:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nash Marc

(Last) (First) (Middle)

3052 ORCHARD DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Operations R&D & Service

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		5,375(1)	D	$5.12	42,785	D
Common Stock	01/21/2026		S		980(1)	D	$4.98	41,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Required number of shares sold by the reporting person to cover partial tax withholding obligations in connection with the vesting of an aggregate of 14,839 shares of Common Stock underlying RSUs granted to the reporting person on June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

	By: John L Brottem For: Marc Nash	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.